

Leveraging Existing Clinical Data for Extrapolation to Pediatric Uses of Medical Devices: Final Guidance

Jacqueline Francis, MD, MPH
Medical Officer
Office of Medical Device Evaluation

Food and Drug Administration (FDA)
Center for Devices and Radiological Health (CDRH)

Objectives

- Provide context for and overview of the Guidance
- Review the extrapolation decision process and examples



CONTEXT AND OVERVIEW

Promote Pediatric Medical Device Development

- The FDA is dedicated to promoting timely access to safe and effective medical devices for all patients, and recognizes the unique needs of pediatric patients
- Despite a recognized need, relatively few medical devices have pediatric-specific indications and labeling
- The Final Guidance proposes a framework to leverage appropriate data for minimizing risk to pediatric patients while maximizing access to medical devices indicated for pediatric patients
- The approach may stimulate growth in the number of devices indicated and labeled for pediatric patients

Regulatory Background

- Regulatory authority allowing for extrapolation
 - Title III of the Food and Drug Administration Amendments Act (FDAAA) is the Pediatric Medical Device Safety and Improvement Act (PMDSIA) of 2007
 - PMDSIA specifically authorized the use of adult data to demonstrate pediatric effectiveness
 - CDRH believes extrapolation for safety is also appropriate in some circumstances

What is Extrapolation?

“Extrapolation” refers to the leveraging process where an indication in a new pediatric patient population can be supported by existing data from a studied population

- When existing data are relevant to a pediatric indication and determined to be valid scientific evidence, it may be appropriate to extrapolate such data for pediatric use

Pediatrics Definition

Age ranges for pediatric subpopulations:

- Neonates: from birth to 1 month of age
- Infants: greater than 1 month to 2 years of age
- Children: greater than 2 to 12 years of age
- Adolescents: greater than 12 through 21 years of age (up to but not including the 22nd birthday)



Challenges to Support Pediatric Indications

- Small and diffusely scattered potential study populations
 - May confound optimal trial size
- Enrollment and consent procedures
 - May increase trial time
- Increased variation in physiology, pathophysiology, anatomy, and human factors as compared to adults
 - Challenges development of appropriate technologies

Because of these challenges, adult devices are used off-label in
pediatrics

Why Consider Extrapolation?

Leveraging relevant available clinical data when appropriate, may

- Lead to more devices being approved for pediatric indications
- Increase availability of medical devices with appropriate labeling to support safe and effective device use in pediatric patients
- Streamline the process for establishing a pediatric intended use claim
- Enhance and encourage pediatric device development programs

Final Guidance Document Highlights

- Background
 - Regulatory History
 - The purpose and potential benefits of extrapolation
- Extrapolation Decision Process
 - Figure 1 provides complete decision tree
 - Full vs. partial extrapolation
 - Extrapolation for effectiveness vs. safety
- Examples and Statistical Methodology for Extrapolation
 - Appendix
 - Statistical guidance on potential methods
 - Six hypothetical and one actual example

Objectives of Guidance

- Increase availability of safe and effective pediatric devices by providing a roadmap for leveraging relevant existing clinical data for use in premarket approval applications (PMAs), humanitarian device exemptions (HDEs), and *de novo* requests
- Explain the circumstances in which the FDA believes it may be appropriate to leverage existing clinical data to support pediatric device indications and labeling
- Outline the approach FDA uses to determine whether extrapolation is appropriate, and if so, to what extent the data can be leveraged
- Describe suggested statistical methodology that may be used to leverage the data in a way that increases precision for pediatric inferences

Guiding Principles

- Fairly and responsibly serve the need of pediatric patients
 - For devices with appropriate labeling to support safe and effective pediatric use
- Guidance does not change
 - threshold for approval
 - need for valid scientific evidence
- Appropriateness of extrapolation is considered
 - *case by case*, guided by the decision tree
 - separately for effectiveness and safety

Determination of Appropriateness of Extrapolation

Three factors:

1. Similarity

- Of existing adult response data and/or population characteristics to the intended pediatric sub-population

2. Quality

- Study design
- Data collection
- Measurement

3. Fair and responsible support of

- Reasonable assurance of safety and effectiveness (or probable benefit for HDEs)
- Valid scientific evidence



Extrapolation Decision Tree

General Considerations

Relevance of Data

- Does the disease or condition occur in a pediatric (sub)population?
- Endpoint in data set relevant to intended pediatric (sub)population?

Similarity of response to intervention

- Device characteristics
- Disease characteristics
- Population characteristics

Quality of Data

- Is the adult/other population data of sufficient quality to demonstrate a reasonable assurance of safety and effectiveness (or probable benefit for HDEs) in pediatric (sub)population?
- If not, is data of sufficient quality for partial extrapolation?

Possible Extrapolation Decisions

- **Full extrapolation:** existing clinical data are used directly (i.e., as a complete substitute) for prospective pediatric clinical data
- **Partial extrapolation:** existing data are combined via a statistical model with pediatric data sources or prospective pediatric clinical data
 - Partial extrapolation permits utilization of existing clinical data to support demonstration of device safety or effectiveness for use in pediatric patients, with the expectation that some pediatric data are necessary
- If not appropriate or insufficient to meet the threshold of valid scientific evidence, data will not be extrapolated


Extrapolation Does not Imply Approval

- A conclusion that extrapolated data may be used does not necessarily mean the data will support an approval decision
- If extrapolation is deemed appropriate, the data would be considered in conjunction with the totality of evidence to either support or not support a reasonable assurance of safety and effectiveness (or probable benefit)



EXTRAPOLATION DECISION TREE AND EXAMPLES

Figure 1: Decision Tree



* Note that if all five questions in Box C are answered “no”, the direction from C is “no”. If at least one of the five is answered “yes”, the direction from C is “yes”.

***The agency relies upon only valid scientific evidence to determine whether there is reasonable assurance that a device is safe and effective. Valid scientific evidence is evidence from well-controlled investigations, partially controlled studies, studies and objective trials without matched controls, well-documented case histories conducted by qualified experts, and reports of significant human experience with a marketed device, from which it can fairly and responsibly be concluded by qualified experts that there is reasonable assurance of the safety and effectiveness of a device under its conditions of use. 21 CFR 860.7(c)(1)&(2).”

Hypothetical Example: Full Extrapolation - Pleural Sealant



- A gel that is used as a pleural air leak sealant is proposed to be indicated for a pediatric population (aged 2–21)
- The gel is currently approved for adults in the closure of remaining visible air leaks incurred during open resection of lung parenchyma, after standard sutures have been applied
 - The same condition can occur in pediatrics
- The measure of device effectiveness used to gain approval was that the patient remained free of air leaks 1 month post-surgery

Actual Extrapolation – Partial Extrapolation – Pedi Heart Valve



- Disease is identified as being the same for pediatrics as for adults
- Primary endpoint for effectiveness would be similar in both a pediatric study and adult study (Decision Tree Questions A and B)
 - Therefore, the adult data are considered relevant

Next Steps

Implementation

- CDRH will use pediatric expertise in the evaluation of any application in which extrapolation is considered
- CDRH is developing the PEDs (Pediatric Extrapolation for Devices) Team
 - A centralized group with pediatric expertise
 - Available for consultation regarding extrapolation
 - Enhanced consistency and standardization with respect to extrapolation decisions



Concluding Remarks

- Despite a recognized need, relatively few medical devices have pediatric-specific indications and labeling
- The guidance proposes a framework for leveraging existing data to augment availability of medical devices indicated and labeled for pediatric patients
- The guidance provides clarity and predictability for device sponsors and enhances consistency within FDA regarding decisions involving extrapolation



Thank You

Additional Slides



KEY CHANGES

Changes From Draft Guidance

- Clarifies and explains the following
 - The guidance applies to PMAs, HDEs and now *de novo* requests where a pediatric indication is sought
 - PMDSIA states that extrapolated data may be used to support a “reasonable assurance of effectiveness (RASE)”
 - Extrapolation for safety may be appropriate in some circumstances
 - PMAs and *de novo* requests both require a demonstration of RASE
 - HDEs require a demonstration of safety and probable benefit
 - Extrapolated data may be particularly useful in HDEs given the rarity of the disease/condition addressed

Changes From Draft Guidance

- Clarifies the concept of “borrowing strength”
 - Quantitative information provided by existing adult/population data may be incorporated in one of two ways:
 - As a substitute for any potential pediatric data
 - As a supplement to “new” pediatric data considered in the context of a statistical model



Changes From Draft Guidance

- Clarifies how to determine “similarity in device effects”
 - Both the direction and magnitude of the device effect should be considered
 - By direction of device effect, we mean that if the device has a benefit for adults, it should also have a benefit for pediatrics
 - The magnitude of benefit should also be similar between populations